JP2019147832A5 - - Google Patents

Download PDF

Info

Publication number
JP2019147832A5
JP2019147832A5 JP2019094350A JP2019094350A JP2019147832A5 JP 2019147832 A5 JP2019147832 A5 JP 2019147832A5 JP 2019094350 A JP2019094350 A JP 2019094350A JP 2019094350 A JP2019094350 A JP 2019094350A JP 2019147832 A5 JP2019147832 A5 JP 2019147832A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
phthalate
enteric coating
composition according
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019094350A
Other languages
English (en)
Other versions
JP6896792B2 (ja
JP2019147832A (ja
Filing date
Publication date
Priority claimed from JP2018017332A external-priority patent/JP2018087220A/ja
Application filed filed Critical
Publication of JP2019147832A publication Critical patent/JP2019147832A/ja
Publication of JP2019147832A5 publication Critical patent/JP2019147832A5/ja
Application granted granted Critical
Publication of JP6896792B2 publication Critical patent/JP6896792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (13)

  1. (i)唯一のフマル酸エステル活性物質として、フマル酸ジメチル、
    (ii)１またはそれ以上の腸溶コーティングポリマー、および
    (iii)１またはそれ以上の医薬的に許容される賦形剤、を含み、
    該フマル酸ジメチルを該組成物中５０−９０％（重量）含有して、人（in vivo）における制御放出が可能な、経口医薬組成物。
  2. 該組成物が錠剤である、請求項１に記載の医薬組成物。
  3. 該組成物がカプセルである、請求項１に記載の医薬組成物。
  4. 該組成物がペレットまたはビーズである、請求項１に記載の医薬組成物。
  5. 該組成物が顆粒である、請求項１に記載の医薬組成物。
  6. 該組成物が微結晶である、請求項１に記載の医薬組成物。
  7. 当該１またはそれ以上の腸溶コーティングポリマーを含むコーティングが含まれる、請求項１に記載の医薬組成物。
  8. 該錠剤が、当該１またはそれ以上の腸溶コーティングポリマーを含むコーティングを含む、請求項２に記載の医薬組成物。
  9. 該ペレットまたはビーズが、当該１またはそれ以上の腸溶コーティングポリマーを含むコーティングを含む、請求項４に記載の医薬組成物。
  10. 該顆粒が、当該１またはそれ以上の腸溶コーティングポリマーを含むコーティングを含む、請求項５に記載の医薬組成物。
  11. 該微結晶が、当該１またはそれ以上の腸溶コーティングポリマーを含むコーティングを含む、請求項６に記載の医薬組成物。
  12. 当該１またはそれ以上の腸溶コーティングポリマーが、ポリアクリルアミド、フタレート誘導体、炭水化物の酸フタレート、アミロースアセテートフタレート、セルロースアセテートフタレート、セルロースエステルフタレート、セルロースエーテルフタレート、ヒドロキシプロピルセルロースフタレート、ヒドロキシプロピルエチルセルロースフタレート、ヒドロキシプロピルメチルセルロースフタレート、メチルセルロースフタレート、ポリビニルアセテートフタレート、ポリアクリルメタクリル酸コポリマー、セラックまたはビニルアセテートおよびクロトン酸コポリマーを含む、請求項１に記載の医薬組成物。
  13. 当該１またはそれ以上の腸溶コーティングポリマーが、ポリアクリルメタクリル酸コポリマーである、請求項１２に記載の医薬組成物。
JP2019094350A 2004-10-08 2019-05-20 フマル酸エステルを含む制御放出医薬組成物 Active JP6896792B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
DKPA200401546 2004-10-08
DKPA200401546 2004-10-08
DKPA200401736 2004-11-10
DKPA200401736 2004-11-10
DKPA200500211 2005-02-11
DKPA200500211 2005-02-11
DKPA200500419 2005-03-23
DKPA200500419 2005-03-23
US69151305P 2005-06-16 2005-06-16
US60/691,513 2005-06-16
JP2018017332A JP2018087220A (ja) 2004-10-08 2018-02-02 フマル酸エステルを含む制御放出医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018017332A Division JP2018087220A (ja) 2004-10-08 2018-02-02 フマル酸エステルを含む制御放出医薬組成物

Publications (3)

Publication Number Publication Date
JP2019147832A JP2019147832A (ja) 2019-09-05
JP2019147832A5 true JP2019147832A5 (ja) 2019-10-17
JP6896792B2 JP6896792B2 (ja) 2021-06-30

Family

ID=50726313

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2007535023A Pending JP2008515822A (ja) 2004-10-08 2005-10-07 フマル酸エステルを含む制御放出医薬組成物
JP2012267572A Pending JP2013064007A (ja) 2004-10-08 2012-12-06 フマル酸エステルを含む制御放出医薬組成物
JP2015139809A Pending JP2015227350A (ja) 2004-10-08 2015-07-13 フマル酸エステルを含む制御放出医薬組成物
JP2018017332A Pending JP2018087220A (ja) 2004-10-08 2018-02-02 フマル酸エステルを含む制御放出医薬組成物
JP2019094350A Active JP6896792B2 (ja) 2004-10-08 2019-05-20 フマル酸エステルを含む制御放出医薬組成物

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2007535023A Pending JP2008515822A (ja) 2004-10-08 2005-10-07 フマル酸エステルを含む制御放出医薬組成物
JP2012267572A Pending JP2013064007A (ja) 2004-10-08 2012-12-06 フマル酸エステルを含む制御放出医薬組成物
JP2015139809A Pending JP2015227350A (ja) 2004-10-08 2015-07-13 フマル酸エステルを含む制御放出医薬組成物
JP2018017332A Pending JP2018087220A (ja) 2004-10-08 2018-02-02 フマル酸エステルを含む制御放出医薬組成物

Country Status (19)

Country Link
US (29) US20140099364A2 (ja)
EP (9) EP2792349A3 (ja)
JP (5) JP2008515822A (ja)
CY (5) CY1113792T1 (ja)
DE (4) DE202005022112U1 (ja)
DK (4) DK2801355T3 (ja)
ES (5) ES2525495T3 (ja)
FR (1) FR15C0074I2 (ja)
HK (1) HK1108836A1 (ja)
HR (1) HRP20170677T1 (ja)
HU (3) HUE028342T2 (ja)
LT (2) LT1799196T (ja)
LU (1) LU92871I2 (ja)
ME (2) ME02253B (ja)
PL (4) PL2801355T3 (ja)
PT (4) PT1799196T (ja)
RS (2) RS55936B1 (ja)
SI (4) SI2316430T1 (ja)
WO (1) WO2006037342A2 (ja)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
US20070027076A1 (en) 2003-09-09 2007-02-01 Fumapham Ag Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
RS55936B1 (sr) * 2004-10-08 2017-09-29 Forward Pharma As Farmaceutske kompozicije sa kontrolisanim oslobađanjem koje sadrže estar fumarne kiseline
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
EP1951206A1 (en) * 2005-10-07 2008-08-06 Aditech Pharma AB Controlled release pharmaceutical compositions comprising a fumaric acid ester
US20070142905A1 (en) * 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
CN101365432B (zh) * 2005-12-16 2011-06-22 默沙东公司 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
WO2008012621A2 (en) * 2006-07-25 2008-01-31 Vecta, Ltd. Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
EP2139467B1 (en) 2007-02-08 2016-09-21 Biogen MA Inc. Neuroprotection in demyelinating diseases
PL2137537T3 (pl) 2007-02-08 2013-10-31 Biogen Ma Inc Kompozycje i zastosowania do leczenia stwardnienia rozsianego
CA2806444C (en) 2008-08-19 2016-02-23 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate
HK1252751A1 (zh) * 2009-01-09 2019-05-31 Fwp Ip Aps 包含溶蝕骨架中的一種或多種富馬酸酯的藥物製劑
EP2379062A1 (en) * 2009-01-09 2011-10-26 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
SI2379063T2 (sl) 2009-01-09 2021-09-30 Fwp Ip Aps Farmacevtska formulacija, ki obsega enega ali več estrov fumarne kisline v tableti v erozivnem matriksu
CN104523673A (zh) * 2009-04-29 2015-04-22 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗
EP2533634B1 (en) 2010-02-12 2015-10-21 Biogen MA Inc. Neuroprotection in demyelinating diseases
EP2544667B1 (en) * 2010-03-09 2018-11-14 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
SI2694471T1 (sl) * 2011-04-08 2017-12-29 Bracco Imaging S.P.A. Postopek priprave sulfatiranega derivata 3,5-dijodo-O-(3-jodofenil)-L-tirozina
ME02960B (me) 2011-06-08 2018-07-20 Biogen Ma Inc Postupak za pripremu visoko-čistog i kristalnog dimetil fumarata
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
EP2782561A1 (en) * 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130216615A1 (en) * 2012-02-07 2013-08-22 David Goldman Pharmaceutical Compositions Containing Dimethyl Fumarate
MX2014009511A (es) 2012-02-07 2014-10-24 Xenoport Inc Compuestos de fumarato de morfolinoalquilo, composiciones farmaceuticas y metodos de uso.
JP2015526476A (ja) 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014100728A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium substituted fumarate derivatives
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
ES2683355T3 (es) 2013-03-14 2018-09-26 Alkermes Pharma Ireland Limited Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3027767A1 (en) * 2013-08-01 2016-06-08 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CA2918846A1 (en) * 2013-08-26 2015-03-05 Forward Pharma A/S Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
WO2015035184A1 (en) 2013-09-06 2015-03-12 Xenoport, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
SG10201913080VA (en) * 2013-12-12 2020-03-30 Almirall Sa Pharmaceutical compositions comprising dimethyl fumarate
WO2015089420A1 (en) * 2013-12-13 2015-06-18 Biogen Idec Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
NZ723269A (en) 2014-02-24 2017-04-28 Alkermes Pharma Ireland Ltd Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
WO2015138917A1 (en) 2014-03-14 2015-09-17 Biogen Ma Inc. Dimethyl fumarate and vaccination regimens
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2015161113A1 (en) * 2014-04-16 2015-10-22 Zynga Inc. Systems and methods of incentivizing game play
AU2015328676B2 (en) * 2014-10-08 2017-07-20 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA41139A (fr) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
KR102283582B1 (ko) 2014-12-23 2021-07-30 한미약품 주식회사 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
WO2016113754A2 (en) * 2015-01-14 2016-07-21 Leiutis Pharmaceuticals Pvt, Ltd. Novel oral dosage forms of dimethyl fumarate
SG10201907289VA (en) * 2015-02-08 2019-09-27 Alkermes Pharma Ireland Ltd Monomethylfumarate prodrug compositions
EP3270911A4 (en) * 2015-03-17 2018-08-29 Hetero Labs Limited Pharmaceutical compositions of dimethyl fumarate
MA41785A (fr) * 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
AU2016273068A1 (en) * 2015-06-01 2017-12-21 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
AU2016279997B2 (en) 2015-06-17 2021-10-21 Biogen Ma Inc. Dimethyl fumarate particles and pharmaceutical compositions thereof
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017060420A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
WO2017129370A1 (en) * 2016-01-28 2017-08-03 Zaklady Farmaceutyczne Polpharma S.A. Process for preparation of a granulate comprising dimethyl fumarate
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
WO2017139331A1 (en) 2016-02-11 2017-08-17 Biogen Ma Inc. Pharmaceutical bead formulations comprising dimethyl fumarate
CN110636838A (zh) 2017-06-23 2019-12-31 阿尔米雷尔有限公司 包含反丁烯二酸二甲酯的药物组合物
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
TR201818293A2 (tr) * 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül
RU2742745C1 (ru) * 2019-09-24 2021-02-10 Акционерное общество "Исследовательский Институт Химического Разнообразия" Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
US20230172894A1 (en) 2020-05-06 2023-06-08 Imcyse Sa Combination treatment for fumarate-related diseases
FR3122850A1 (fr) * 2021-05-11 2022-11-18 Faurecia Sièges d'Automobile Siège de véhicule pliable
TW202313006A (zh) 2021-05-28 2023-04-01 美商安進公司 阿普斯特配製物
WO2023084320A1 (en) * 2021-11-11 2023-05-19 V-Ensure Pharma Technologies Private Limited Reconstitutable, single use antidiabetic compositions
US20240010618A1 (en) * 2021-12-23 2024-01-11 Glenmark Lofe Science Limited Process for the preparation of brivaracetam
CN116524199B (zh) * 2023-04-23 2024-03-08 江苏大学 一种基于PReNet渐进式网络的图像去雨方法及装置

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2764609A (en) * 1953-07-24 1956-09-25 Monsanto Chemicals Isomerization of dialkyl maleates to dialkyl fumarates
US3078302A (en) * 1958-09-25 1963-02-19 Monsanto Chemicals Production of dialkyl fumarates
GB1153927A (en) 1966-08-25 1969-06-04 Wilhelm Hoerrmann Medicinal Composition Suitable For Treating Diseases Of The Retina
US4952594A (en) * 1973-06-18 1990-08-28 Mercer James B Reagents and method for therapeutic treatment of multiple sclerosis
DE2530372A1 (de) 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2703964A1 (de) 1975-07-08 1978-08-03 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
US4145438A (en) * 1975-09-10 1979-03-20 Fisons Limited Method for treatment of eczema or psoriasis
DE2621214C3 (de) 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE2732131A1 (de) 1977-07-15 1979-01-25 Bayer Ag Verfahren zur herstellung von seitenstaendige hydroxylgruppen aufweisenden isocyanat-polyadditionsprodukten
DE2749188C2 (de) 1977-11-03 1981-11-12 Bayer Ag, 5090 Leverkusen Vorrichtung zum automatischen Einführen eines schnellaufenden Fadens in einen Fadenführungskanal einer Fadenbehandlungsvorrichtung
DE2840498C2 (de) 1978-09-18 1980-04-10 Walter Dr. 6700 Ludwigshafen Schweckendiek Pharmazeutische Zubereitungen zur Behandlung von Psoriasis
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US4693896A (en) 1985-10-07 1987-09-15 Fmc Corporation Ethylcellulose-coated, gastric-disintegrable aspirin tablet
US4855305A (en) 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
DE3711155A1 (de) * 1987-04-02 1988-10-13 Bayer Ag Verfahren zur herstellung von maleinsaeuredimethylester
IL83775A (en) 1987-09-04 1991-12-15 Dexter Chemical Corp Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) * 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5023245A (en) * 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
US4911917A (en) * 1988-06-28 1990-03-27 Hauser-Kuhrts, Inc. Cholesterol-lowering combination comopsitions of magnesium salt and niacin
US4965252A (en) 1988-06-28 1990-10-23 Hauser-Kuhrts, Inc. Cholesterol-lowering combination compositions of guar gum and niacin
DE3834794A1 (de) 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
GB2253346A (en) 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
US5484610A (en) 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
US5246947A (en) * 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
FR2694693B1 (fr) 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
EP0621032B1 (en) * 1993-04-23 2000-08-09 Novartis AG Controlled release drug delivery device
US5434185A (en) 1993-05-17 1995-07-18 The University Of Kentucky Research Foundation Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
MX9605419A (es) 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
US5589504A (en) * 1994-07-26 1996-12-31 Cornell Research Foundation, Inc. Treatment of newborn jaundice
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5716625A (en) 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5804203A (en) * 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
EP0737471A3 (fr) * 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
EP0821587A4 (en) 1995-04-19 1999-05-19 Lipoprotein Technologies Inc COMPOSITIONS, KITS AND METHODS FOR ADMINISTERING ANTILIPEMICS AND MEDICINES AGAINST PLATELET AGGREGATION
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
WO1998004290A2 (en) 1996-07-26 1998-02-05 Perrine Susan P Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
IL136196A (en) 1998-01-22 2004-07-25 Zentaris Ag Solid pharmaceutical preparations containing Miltphosin for oral administration for the treatment of leishmaniasis
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
AU3024399A (en) * 1998-04-03 1999-10-25 Bm Research A/S Controlled release composition
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
KR100297705B1 (ko) * 1999-03-29 2001-10-29 김덕중 낮은 온저항과 높은 항복전압을 갖는 전력용 반도체소자
US6537584B1 (en) 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
AU3228301A (en) * 2000-02-15 2001-08-27 Showa Denko Kabushiki Kaisha Process for producing fumaric ester
EP1296923B3 (en) * 2000-02-16 2012-04-11 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
IT1317042B1 (it) * 2000-06-14 2003-05-26 Biosalts Srl Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono.
EP1172101A1 (en) * 2000-06-20 2002-01-16 Helsinn Healthcare S.A. The use of nimesulide for the treatment of psoriasis and psoriatic arthritis
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
DE10101307A1 (de) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
PL392748A1 (pl) * 2001-01-12 2011-05-09 Fumapharm Ag Amidy kwasu fumarowego
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
CN100579514C (zh) 2001-07-06 2010-01-13 生命周期药物公司 通过受控制的凝聚而制备颗粒物的方法以及提高生物利用度的方法
NO20014746D0 (no) 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
TWI239520B (en) * 2001-10-12 2005-09-11 Konica Corp Objective lens, optical element, optical pick-up apparatus and optical information recording and/or reproducing apparatus equipped therewith
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
EP1446118B1 (en) 2001-11-13 2008-01-09 Pharmacia Corporation Oral dosage form of parecoxib
JP3796165B2 (ja) * 2001-11-20 2006-07-12 株式会社クラレ 癒着防止材
US6613800B1 (en) * 2001-12-03 2003-09-02 Steven A. Smith Method and compositions for treating psoriasis, eczema, seborrhea and arthritis
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
PT1485078E (pt) 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
DE10214031A1 (de) 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
US20030185915A1 (en) * 2002-03-28 2003-10-02 Jaime Carlo Synergetic composition for the treatment of psoriasis and other skin disorders and method therefor
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
US20030219456A1 (en) * 2002-05-21 2003-11-27 Taing Ok Method of utilization of zygosaccharomyces rouxii
US6830759B2 (en) 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
DE60305053T2 (de) 2002-08-19 2006-08-31 Glaxo Group Ltd., Greenford Pyrimidinderivate als selektive cox-2-inhibitoren
US20070053994A1 (en) 2003-03-27 2007-03-08 Egil Jellum Anti-inflammatory treatment
PL1534305T3 (pl) 2003-05-07 2007-03-30 Osteologix As Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
EP1622629B1 (en) 2003-05-07 2013-07-10 Osteologix A/S Controlled-release composition containing a strontium salt
PT2266584E (pt) 2003-05-07 2012-12-19 Osteologix As Composição com estrôncio e vitamina d para a profilaxia/tratamento de patologias da cartilagem e/ou do osso
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
MEP3608A (en) 2003-08-08 2011-05-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
US20070027076A1 (en) 2003-09-09 2007-02-01 Fumapham Ag Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
JP2007530683A (ja) 2004-03-31 2007-11-01 ビーピーエスアイ ホールディングス，インコーポレーテッド 経口摂取可能な基材の腸溶性コーティング
TW200603792A (en) 2004-04-23 2006-02-01 Pharmacia & Upjohn Co Llc Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors
CN1245873C (zh) 2004-08-21 2006-03-22 王立峰 富马酸二甲酯微胶囊及其制备方法
RS55936B1 (sr) 2004-10-08 2017-09-29 Forward Pharma As Farmaceutske kompozicije sa kontrolisanim oslobađanjem koje sadrže estar fumarne kiseline
CN101056624A (zh) 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1812374A1 (en) 2004-11-10 2007-08-01 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
DE102005022845A1 (de) * 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
US20070071819A1 (en) * 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
CA2614110A1 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
DE602006011910D1 (de) * 2005-07-07 2010-03-11 Aditech Pharma Ag Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1951206A1 (en) 2005-10-07 2008-08-06 Aditech Pharma AB Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2007042035A2 (en) 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
EP2426212A1 (en) * 2006-02-15 2012-03-07 Md Bioalpha Co., Ltd. Method for controlling NAD(P)/NAD(P)H ratio by oxidoreductase
WO2007148744A1 (ja) 2006-06-21 2007-12-27 Santen Pharmaceutical Co., Ltd. フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤
BRPI0716174A2 (pt) 2006-09-01 2013-09-24 Cv Therapeutics Inc mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio.
PL2137537T3 (pl) * 2007-02-08 2013-10-31 Biogen Ma Inc Kompozycje i zastosowania do leczenia stwardnienia rozsianego
EP2139467B1 (en) * 2007-02-08 2016-09-21 Biogen MA Inc. Neuroprotection in demyelinating diseases
BRPI0807739B1 (pt) * 2007-02-21 2018-06-26 Mochida Pharmaceutical Co., Ltd. Composição para o tratamento de doenças da cartilagem
WO2008129698A1 (ja) 2007-04-12 2008-10-30 Panasonic Corporation 電源システムおよび組電池の充電方法
WO2008134013A2 (en) 2007-04-25 2008-11-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical excipient complex
US20080274182A1 (en) 2007-05-03 2008-11-06 Regina Helena Alida Boekema Tablet coatings made from modified carboxymethylcellulose materials
JP2010532358A (ja) 2007-07-01 2010-10-07 ピーター ハバウシ，ジョセフ 咀嚼可能外層を有する配合剤
KR20090028047A (ko) * 2007-09-13 2009-03-18 경북대학교 산학협력단 디메틸푸마레이트의 신규 용도
CN101318901A (zh) 2008-06-17 2008-12-10 健雄职业技术学院 一种富马酸二甲酯的合成新工艺
CA2806444C (en) * 2008-08-19 2016-02-23 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate
JP5420877B2 (ja) * 2008-10-07 2014-02-19 テイカ製薬株式会社 眼科用剤
SI2379063T2 (sl) * 2009-01-09 2021-09-30 Fwp Ip Aps Farmacevtska formulacija, ki obsega enega ali več estrov fumarne kisline v tableti v erozivnem matriksu
EP2379062A1 (en) * 2009-01-09 2011-10-26 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
CN101475477A (zh) 2009-01-23 2009-07-08 上海化学试剂研究所 反丁烯二酸二甲酯的制备方法
WO2010113096A1 (en) * 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
CN104523673A (zh) * 2009-04-29 2015-04-22 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗
CN101701943A (zh) 2009-11-05 2010-05-05 宁波中普检测技术服务有限公司 气相色谱-质谱联用测定产品中富马酸二甲酯的方法
EP2533634B1 (en) 2010-02-12 2015-10-21 Biogen MA Inc. Neuroprotection in demyelinating diseases
US8927524B2 (en) * 2010-03-11 2015-01-06 Bender Analytical Holding B.V. Sterile alginate-based aqueous composition for medical use and process for the preparation thereof
MX2013013781A (es) 2011-05-26 2014-01-08 Biogen Idec Inc Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina.
ME02960B (me) 2011-06-08 2018-07-20 Biogen Ma Inc Postupak za pripremu visoko-čistog i kristalnog dimetil fumarata
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
US20130216615A1 (en) 2012-02-07 2013-08-22 David Goldman Pharmaceutical Compositions Containing Dimethyl Fumarate
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
KR102092289B1 (ko) * 2013-06-03 2020-03-23 삼성전자주식회사 전자 기기 및 이의 문서 작성 방법
WO2015089420A1 (en) 2013-12-13 2015-06-18 Biogen Idec Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
AU2015328676B2 (en) 2014-10-08 2017-07-20 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
WO2017040272A1 (en) 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
AU2016319444B2 (en) * 2015-09-07 2022-05-12 Mochida Pharmaceutical Co., Ltd. Freeze-dried alginic acid preparation
WO2017151184A1 (en) 2016-02-29 2017-09-08 Banner Life Sciences Llc Fumarate ester dosage forms
WO2017159700A1 (ja) * 2016-03-14 2017-09-21 公益財団法人田附興風会 神経再生誘導材
US10523918B2 (en) 2017-03-24 2019-12-31 Samsung Electronics Co., Ltd. System and method for depth map

Similar Documents

Publication Publication Date Title
JP2019147832A5 (ja)
JP2017019858A5 (ja)
JP2016525572A5 (ja)
JP2012526047A5 (ja)
WO2012091153A3 (en) Orally disintegrating tablet
JP2012525444A5 (ja)
JP2009545560A5 (ja)
JP2015527395A5 (ja)
RU2011145433A (ru) Перорально распадающиеся таблеточные композиции, содержащие комбинации неопиоидных и опиоидных анальгетиков
JP2005320354A5 (ja)
JP2017532363A5 (ja)
JP2011502140A5 (ja)
JP2020523335A5 (ja)
JP2009521526A5 (ja)
RU2015107517A (ru) Фармацевтические композиции мемантина
JP2014533656A5 (ja)
JP2019513800A5 (ja)
US20140178468A1 (en) Multiparticulate extended-release composition of mesalamine
HRP20231012T1 (hr) Novi sastav s odgođenim oslobađenjem za peroralno davanje
JP2010518002A5 (ja)
JP2015531749A5 (ja)
JP2019513801A5 (ja)
US9132092B1 (en) Pharmaceutical composition of doxycycline
RU2013150254A (ru) Пероральный твердый препарат комбинированного противотуберкулезного лекарственного средства и способ его получения
WO2012014052A4 (en) Novel coated extended release pharmaceutical compositions containing paliperidone